Healthcare Industry News: Roche
News Release - November 28, 2016
Synthorx Appoints Patrick J. Doyle as Chief Business OfficerSAN DIEGO, Nov. 28, 2016 -- (Healthcare Sales & Marketing Network) -- Synthorx Inc., a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, announced today the appointment of Patrick J. Doyle as chief business officer.
"Patrick is an accomplished leader in the life sciences industry with significant experience in international business development and strategic partnerships," said Court Turner, president and CEO of Synthorx. "Patrick's broad corporate strategy and business development expertise will be important to Synthorx as we strengthen existing partnerships and explore new opportunities for using our expanded genetic alphabet technology to discover and develop improved protein therapeutics."
"Synthorx is breaking new ground in the drug development space to design and scale-up new classes of biologics with novel chemical functionality and better therapeutic profiles," said Mr. Doyle. "I look forward to working with the Synthorx team and our partners to apply the company's unique drug design technology to previously hard-to-drug targets in oncology, pain, autoimmune and metabolic disorders."
Mr. Doyle has more than 20 years of experience with worldwide business development, licensing and leadership of the pharmaceutical R&D process. Prior to joining Synthorx, Mr. Doyle held various C-suite positions at Kinemed, Kareus Therapeutics, Syntaxin and Metabolex, where he grew the business platforms significantly via global collaborations and financing. In addition, Mr. Doyle has held top management positions at Novo Nordisk, Roche and PPD. He completed his Ph.D. thesis and received his B.S. in pharmacology from the University of Sunderland in England.
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx's expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins of any size, from small peptides to large biologics, and to manufacture these improved proteins at scale. Synthorx's unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. Synthorx is working internally and in collaboration with pharmaceutical companies toward the design and discovery of first-in-class drugs for a variety of therapeutic areas. Synthorx's investors include RA Capital Management, Avalon Ventures, and Correlation Ventures. The company was founded based on important discoveries in Dr. Floyd Romesberg's lab at The Scripps Research Institute. The company is headquartered in La Jolla, Calif.
For more information, please visit www.synthorx.com and follow on Twitter @synthorx.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.